Advertisement

Heart and Vessels

, Volume 34, Issue 12, pp 1952–1960 | Cite as

Acetazolamide as a potent chloride-regaining diuretic: short- and long-term effects, and its pharmacologic role under the ‘chloride theory’ for heart failure pathophysiology

  • Hajime KataokaEmail author
Original Article
  • 91 Downloads

Abstract

According to the “chloride theory” for heart failure (HF) pathophysiology, manipulation of the serum chloride concentration is an important therapeutic target. This study determined the short- and long-term effects of acetazolamide (Diamox), a potential chloride-regaining diuretic, on peripheral blood, serum electrolytes, and renal function. Effects of low-dose Diamox (250–500 mg/day) were evaluated in 30 HF patients for whom Diamox was added as de-novo/add-on decongestion therapy for acutely worsening HF (n = 18) or as modification therapy for serum hypochloremia in stable HF ( < 100 mEq/L; n = 12). Peripheral hematologic tests were performed at baseline, and at short- ( ≤ 10 days) and long-term ( ~ 60 days) time-points. In all 30 study patients of both groups, the serum chloride concentration increased in the short-term and even further over the long-term. The serum potassium concentration constantly decreased throughout the study period. Both the blood urea nitrogen and serum creatinine concentrations increased in the short-term, but returned to baseline levels over the long-term. Responders to Diamox (n = 13; defined by HF resolution and body weight loss ≥ 1 kg) in the decongestion group exhibited reduced serum b-type natriuretic peptide levels and a markedly increased serum chloride concentration, but the hemoglobin/hematocrit and serum creatinine concentrations did not change after treatment. In conclusion, acetazolamide is a potent candidate “chloride-regaining diuretic” for treating HF patients under the “chloride theory”. Its effect to enhance the serum chloride concentration occurred within 10 days and persisted for at least ~ 60 days. Plasma volume and renal function were preserved under adequate diuretic treatment with acetazolamide.

Keywords

Heart failure Chloride Diuretics Acetazolamide Diamox Electrolyte 

Notes

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

References

  1. 1.
    Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J (1986) Sodium and water balance in chronic congestive heart failure. J Clin Invest 77:1441–1452PubMedPubMedCentralGoogle Scholar
  2. 2.
    Volpe M, Tritto C, DeLuca N, Rubattu S, Rao MAE, Lamenza F, Mirante A, Enea I, Rendina V, Mele AF, Trimarco B, Condorelli M (1993) Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure. Circulation 88(1):1620–1627PubMedGoogle Scholar
  3. 3.
    Sica DA (2006) Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 73(suppl 2):S2–S7PubMedGoogle Scholar
  4. 4.
    Testani JM, Hanberg JS, Arroyo JP, Brisco MA, ter Maaten JM, Wilson FP, Bellumkonda L, Jacoby D, Tang WHW, Parikh CR (2016) Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. Eur J Heart Fail 18:660–668PubMedPubMedCentralGoogle Scholar
  5. 5.
    Hanberg JS, Rao V, ter Maaten JM, Laur O, Brisco MA, Wilson FP, Grodin JL, Assefa M, Broughton JS, Planavsky NJ, Ahmad T, Bellumkonda L, Tang WHW, Parikh CR, Testani JM (2016) Hypochloremia and diuretic resistance in heart failure: mechanistic insights. Circ Heart Fail 9:e003180PubMedGoogle Scholar
  6. 6.
    Kataoka H (2017) Vascular expansion during worsening of heart failure: effects on clinical features and its determinants. Int J Cardiol 230:556–561PubMedGoogle Scholar
  7. 7.
    Kataoka H (2019) Biochemical determinants of changes in plasma volume after decongestion therapy for worsening heart failure. J Card Fail 25:213–217PubMedGoogle Scholar
  8. 8.
    Kataoka H (2017) Proposal for heart failure progression based on the “chloride theory”: worsening heart failure with increased vs. non-increased serum chloride concentration. ESC Heart Fail 4:623–631PubMedPubMedCentralGoogle Scholar
  9. 9.
    Kataoka H (2017) The “chloride theory”, a unifying hypothesis for renal handling and body fluid distribution in heart failure pathophysiology. Med Hypotheses 104:170–173PubMedGoogle Scholar
  10. 10.
    Hilton JG, Kalinsky H (1951) Potentiation of diuretic action of mercuhydrin by ammonium chloride. J Clin Invest 30:1105–1110PubMedPubMedCentralGoogle Scholar
  11. 11.
    Friedberg C, Taymor R, Minor JB, Halpern M (1953) The use of Diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure. N Engl J Med 248:883–889PubMedGoogle Scholar
  12. 12.
    Leaf A, Schwartz WB, Relman AS (1954) Oral administration of a potent carbonic anhydrase inhibitor (“Diamox”): I. Changes in electrolyte and acid-base balance. N Engl J Med 250:759–764PubMedGoogle Scholar
  13. 13.
    Relman AS, Leaf A, Schwartz WB (1954) Oral administration of a potent carbonic anhydrase inhibitor (“Diamox”): II. Its use as a diuretic in patients with severe congestive heart failure. N Engl J Med 250:800–804PubMedGoogle Scholar
  14. 14.
    Rubin AL, Thompson HG Jr, Braveman WS, Luckey EH (1955) The management of refractory edema in heart failure. Ann Intern Med 42:358–368PubMedGoogle Scholar
  15. 15.
    Khan MI (1980) Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J 123:883–887PubMedPubMedCentralGoogle Scholar
  16. 16.
    Caramelo C, Albalate M, Tejedor A, Alcázar TR, Baldoví S, Pérez AG, Marín M (2008) Actuality of the use of acetazolamide as a diuretic: usefulness in refractory edema and in aldosterone-antagonist-related hyperkalemia. Nefrologia 28:234–238PubMedGoogle Scholar
  17. 17.
    Kassamali R, Sica DA (2011) Acetazolamide: a forgotten diuretic agent. Cardiol in Rev 19:276–278Google Scholar
  18. 18.
    Kataoka H (2018) Treatment of hypochloremia with acetazolamide in an advanced heart failure patient and importance of monitoring urinary electrolytes. J Card Cases 17:80–84Google Scholar
  19. 19.
    Kataoka H (2018) Comparison of changes in the plasma volume and renal function between acetazolamide vs conventional diuretics: understanding their mechanical differences according to the chloride theory. Eur Heart J 39:40–41 (abstract) Google Scholar
  20. 20.
    Ghali JK, Tam SW (2010) The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Cardiac Fail 16:419–431Google Scholar
  21. 21.
    Kataoka H, Takada S (2000) The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. J Am Coll Cardiol 35:1638–1646PubMedGoogle Scholar
  22. 22.
    Kataoka H (2012) Ultrasound pleural effusion sign as a useful marker for identifying heart failure worsening in established heart failure patients during follow-up. Congest Heart Fail 18:272–277PubMedGoogle Scholar
  23. 23.
    Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught H, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M (2008) Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 52:1540–1545PubMedGoogle Scholar
  24. 24.
    Kataoka H, Yamasaki Y (2016) Strategy for monitoring decompensated heart failure treated by an oral vasopressin antagonist with special reference to the role of serum chloride: a case report. J Card Cases 14:185–188Google Scholar
  25. 25.
    ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA (2015) Diuretic response in acute heart failure: pathophysiology, evaluation, and therapy. Nat Rev Cardiol 12:184–192PubMedGoogle Scholar
  26. 26.
    Pitt B, Ferreira JP, Zannad F (2017) Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 3:48–57PubMedGoogle Scholar
  27. 27.
    Ferreira JP, Rossignol P, Machu J-L, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, ter Maaten J, Metra M, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F (2017) Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail 19:1284–1293PubMedGoogle Scholar
  28. 28.
    Grodin JL (2016) Pharmacologic approaches to electrolyte abnormalities in heart failure. Curr Heart Fail Rep 13:181–189PubMedGoogle Scholar
  29. 29.
    Urso C, Brucculeri S, Caimi G (2015) Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications. Heart Fail Rev 20:493–503PubMedPubMedCentralGoogle Scholar
  30. 30.
    Wilcox CS (1983) Regulation of renal blood flow by plasma chloride. J Clin Invest 71:726–735PubMedPubMedCentralGoogle Scholar
  31. 31.
    Yunos NM, Bellomo R, Hegarty C, Story D, Colin LH, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572PubMedGoogle Scholar
  32. 32.
    Thongprayoon C, Cheungpasitporn W, Cheng Z, Qian Q (2017) Chloride alterations in hospitalized patients: prevalence and outcome significance. PLoS ONE 12:e0174430PubMedPubMedCentralGoogle Scholar
  33. 33.
    Tojima H, Kunitomo F, Kimura H, Tatsumi K, Kuriyama T, Honda Y (1988) Effects of acetazolamide in patients with the sleep apnea syndrome. Thorax 43:113–119PubMedPubMedCentralGoogle Scholar
  34. 34.
    Javaheri S (2006) Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 173:234–237PubMedGoogle Scholar
  35. 35.
    Cowie MR, Gallagher AM (2017) Sleep disordered breathing and heart failure: what does the future hold? JACC Heart Fail 5:715–723PubMedGoogle Scholar
  36. 36.
    Imiela T, Budaj A (2018) Response to “acetazolamide and cardiac failure. Clin Drug Investig.  https://doi.org/10.1007/s40261-018-0654-0 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Mizuno K (2012) Clinical significance of acid-base balance in an emergency setting in patients with acute heart failure. J Cardiol 60:288–294PubMedGoogle Scholar
  38. 38.
    Otaki Y, Watanabe T, Takahashi H, Hasegawa H, Honda S, Funayama A, Netsu S, Ishino M, Arimoto T, Shishido T, Miyashita T, Miyamoto T, Konta T, Kubota I (2013) Acidic urine is associated with poor prognosis in patients with chronic heart failure. Heart Vessels 28:735–741PubMedGoogle Scholar
  39. 39.
    Kataoka H (2018) Vasopressin antagonist-like effect of acetazolamide in a heart failure patient: a case report. Eur Heart J Case Rep 2(3):1–5Google Scholar
  40. 40.
    Vogiatzis I, Koulouris E, Sidiropoulos A, Giannakoulas C (2013) Acute pulmonary edema after a single oral dose of acetazolamide. Hippokratia 17:177–179PubMedPubMedCentralGoogle Scholar
  41. 41.
    Zimmermann S, Achenbach S, Wolf M, Janka R, Marwan M, Mahler V (2014) Recurrent shock and pulmonary edema due to acetazolamide medication after cataract surgery. Heart Lung 43:124–126PubMedGoogle Scholar
  42. 42.
    Maisey DN, Brown RD (1981) Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J 283:1527–1528Google Scholar
  43. 43.
    Margo CE (1986) Acetazolamide and advanced liver disease. Am J Ophthalmol 101:611–612PubMedGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Internal MedicineNishida HospitalSaikiJapan

Personalised recommendations